This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kadmon Holdings, Inc.
Drug Names(s): KD020
KD020 is a reversible tyrosine kinase inhibitor targeting EGFR, HER2, VEGFR 2/3 and Src.
Kadmon is developing a related drug, KD019, derived from the same drug substance.
Additional information available to subscribers only: